Christine Ardal

Dr. Christine Ardal

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2019 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
CAChristine Ardal
Christine Ardal
MBManica Balasegaram
Manica Balasegaram
RLRamanan Laxminarayan
Ramanan Laxminarayan
DMDavid McAdams
David McAdams
KOKevin Outterson
Kevin Outterson
NSNithima Sumpradit
Nithima Sumpradit

4 December 2025 in Nature Communications
Verified
Journal Article
Open access
KMKyung Moon
Kyung Moon
CCCarmen Coxon
Carmen Coxon
CAChristine Ardal
Christine Ardal
RBRadu Botgros
Radu Botgros
SDSarah Djebara
Sarah Djebara
MCMarco Cavaleri
Marco Cavaleri
Amid rising antimicrobial resistance and limited antibiotic innovation, bacteriophages are gaining attention as potential therapeutics across human health, animal, and food sectors. Despite historical use, their clinical application in humans remains constrained by scientific, industrial, and regulatory challenges. To address these issues, the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) convened sessions with experts from member parties. This perspective synthesizes insights from the TATFAR group, highlighting regulatory differences, research gaps, and opportunities for international collaborations to advance bacteriophage therapy.

21 January 2021 in Bulletin of the World Health Organization
Verified
Journal Article
Open access
CAChristine Ardal
Christine Ardal
EBEnrico Baraldi
Enrico Baraldi
PBPeter Beyer
Peter Beyer
YLYohann Lacotte
Yohann Lacotte
DLDg Joakim Larsson
Dg Joakim Larsson
ISIngrid Smith
Ingrid Smith

1 August 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
CAChristine Ardal
Christine Ardal
EBEnrico Baraldi
Enrico Baraldi
FCFrancesco Ciabuschi
Francesco Ciabuschi
KOKevin Outterson
Kevin Outterson
JRJohn H Rex
John H Rex
DFDavid Findlay
David Findlay

5 April 2018 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
PDF file
CAChristine Ardal
Christine Ardal
EBEnrico Baraldi
Enrico Baraldi
UTUrsula Theuretzbacher
Ursula Theuretzbacher
KOKevin Outterson
Kevin Outterson
JPJens Plahte
Jens Plahte
JRJohn-Arne Røttingen
John-Arne Røttingen
Antibiotic innovation has dwindled to dangerously low levels in the past 30 years. Since resistance continues to evolve, this innovation deficit can have perilous consequences on patients. A number of new incentives have been suggested to stimulate greater antibacterial drug innovation. To design effective solutions, a greater understanding is needed of actual antibiotic discovery and development costs and timelines. Small and medium-sized enterprises (SMEs) undertake most discovery and early phase development for antibiotics and other drugs. This paper attempts to gather a better understanding of SMEs’ targets, costs, and durations related to discovery and early phase development of antibacterial therapies. DRIVE-AB, a project focused on developing new economic incentives to stimulate antibacterial innovation, held a European stakeholder meeting in February 2015. All SMEs invited to this meeting (n = 44) were subsequently sent a survey to gather more data regarding their areas of activity, completed and expected development costs and timelines, and business models. Twenty-five companies responded to the survey. Respondents were primarily small companies each focusing on developing 1 to 3 new antibiotics, focused on pathogens of public health importance. Most have not yet completed any clinical trials. They have reported ranges of discovery and development out-of-pocket costs that appear to be less expensive than other studies of general pharmaceutical research and development (R&D) costs. The duration ranges reported for completing each phase of R&D are highly variable when compared to previously published general pharmaceutical innovation average durations. However, our sample population is small and may not be fully representative of all relevant antibiotic SMEs. The data collected by this study provide important insights and estimates about R&D in European SMEs focusing on antibiotics, which can be combined with other data to design incentives to stimulate antibacterial innovation. The variation implies that costs and durations are difficult to generalize due to the unique characteristics of each antibiotic project and depend on individual business strategies and circumstances.

28 September 2022 in International Journal of Physical Distribution & Logistics Management
Verified
Journal Article
Closed access
VAVictoria Ahlqvist
Victoria Ahlqvist
NDNonhlanhla Dube
Nonhlanhla Dube
MJMarianne Jahre
Marianne Jahre
JLJin Soo Lee
Jin Soo Lee
TKTsegaye Melaku Kebede
Tsegaye Melaku Kebede
CAChristine Ardal
Christine Ardal
Purpose: This paper links supply chain risk management to medicine supply chains to explore the role of policymakers in employing supply chain risk management strategies (SCRMS) to reduce generic medicine shortages.Design/methodology/approach: Using secondary data supplemented with primary data, the authors map and compare seven countries' SCRMS for handling shortage risks in their paracetamol supply chains before and during the first two waves of the COVID-19 pandemic.Findings: Consistent with recent research, the study finds that policymakers had implemented few SCRMS specifically for responding to disruptions caused by COVID-19. However, shortages were largely avoided since multiple strategies for coping with business-as-usual disruptions had been implemented prior to the pandemic. The authors did find that SCRMS implemented during COVID-19 were not always aligned with those implemented pre-pandemic. The authors also found that policymakers played both direct and indirect roles.Research limitations/implications: Combining longitudinal secondary data with interviews sheds light on how, regardless of the level of preparedness during normal times, SCRMS can be leveraged to avert shortages in abnormal times. However, the problem is highly complex, which warrants further research.Practical implications: Supply chain professionals and policymakers in the healthcare sector can use the findings when developing preparedness and response plans.Social implications: The insights developed can help policymakers improve the availability of high-volume generic medicines in (ab)normal times.Originality/value: The authors contribute to prior SCRM research in two ways. First, the authors operationalize SCRMS in the medicine supply chain context in (ab)normal times, thereby opening avenues for future research on SCRM in this context. Second, the authors develop insights on the role policymakers play and how they directly implement and indirectly influence the adoption of SCRMS. Based on the study findings, the authors develop a framework that captures the diverse roles of policymakers in SCRM.